laboratori corp america lh
valuat uncertainti unh/aet impact
keep us hold
head yesterday earn releas thought key driver lh
share would perform covanc busi actual
deliv good result howev despit strength segment
core diagnost servic busi lh share saw pressur management
commentari neg impact aet contract
creat new overhang stock maintain hold given
organ volum growth lab busi notabl posit pama rate
cut limit ebitda growth upsid outsid mani hc provid
find difficult gener posit organ volum growth current environ
highlight lh seven consecut quarter posit organ volum
growth despit strong organ growth quarter medicar
reimburs cut relat pama meaning impact lab segment
oper margin y/i pama-associ rate cut continu flow
next two half year believ lh need reli heavili
strateg achiev ebitda growth lab segment
covanc perform continu exceed expect biotech fund level
suggest busi posit well covanc strong perform
continu oper incom beat consensu expect vs
due strong organ revenu growth effici gener lh launchpad
initi acceler realiz synergi chiltern acquisit move
 expect covanc continu perform well busi
execut cost effici synergi goal stand benefit biotech
fund tailwind detail david windley note acknowledg net
book quarter lower anticip believ
primarili function time sever book shift addit lh newli ink
strateg partnership gener increment book next sever year
still hold rate unh/aet comment creat overhang current
multipl suggest stock appropri valu believ management comment
surround potenti neg revenu net profit impact lh
member lose aet member gain creat slight overhang stock
like limit multipl expans nt mind believ stock
fairli valu current level in-lin w/ histor price-to-earnings delta vs
ep amort non-recur item
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
laboratori corpor america lh
pama-rel reimburs cut like limit lab
segment ebitda growth lh need reli
heavili strateg realiz cost effici
order grow oper earn
covanc continu grow top-lin
ebitda segment stand benefit
increas level biotech fund realiz
management commentari neg impact
aet contract creat new overhang
stock limit nt multipl expans
announc decis acla pama-
lab segment pama-rel reimburs cut
growth
cro segment revenu op incom growth
acceler chiltern acquisit integr
launchpad gener increment cost effici
lh like need reli strateg lab
segment order grow ebitda meaning
ep target multipl in-lin
synergi lab cro segment could drive
acceler growth new order revenu op
incom cro segment
save project launchpad could allow margin
cro segment expand meaning
acla win lawsuit vs method
determin rate within pama need revisit like
lessen neg impact
lab segment continu slowdown us
healthcar util environ loss
volum via dgx inclus within contract
caus volum weak
pama-rel medicar reimburs cut
cro segment integr risk covanc
chiltern could caus synergi fall target
page
pleas see import disclosur inform page report
lh statement earn
page
pleas see import disclosur inform page report
